Liver Regeneration
Conditions
Keywords
pentoxyfilline, liver regeneration, major liver resection, reduction of the I/R injury
Brief summary
The investigators hypothecate that pentoxyfilline increase significantly the liver regeneration and reduces significantly ischemia and reperfusion (I/R) injury in major liver using aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as marker of I/R injury.
Detailed description
Liver resection is for many patients with primary or secondary hepatic malignancies the only curative treatment option. Often, the complete clearance of the hepatic tumor disease can be only achieved by extended liver resections. Clinical studies have demonstrated that intra-operative blood loss is associated reduced outcome after major liver resection. An effective strategy to reduce blood loss is the occlusion of the portal triad (Pringle manoeuvre). On the other hand, inflow occlusion results in ischemia- and reperfusion (I/R) injury. Randomized trials have shown that ischemic preconditioning (10 min clamping, 10 min reperfusion) and intermittent clamping (15 min clamping, 5 min reperfusion) result in reduction of the I/R injury. Another potential strategy to reduce I/R injury is the pharmacological protection. One promising drug is pentoxyfilline (PTF) which has vasodilative and hemorheologic effects. Furthermore, PTF suppresses the TNF release. These effects may be also protective in major liver resection under inflow occlusion (Pringle manoeuvre)and increase the liver regeneration. Therefore, we designed a randomised prospective trial to investigate the effects of PTF treatment in liver resection under inflow occlusion. The specific aims of the research project are:The investigators hypothecate that pentoxyfilline increases significantly the liver regeneration and reduces significantly ischemia and reperfusion (I/R) injury in liver using aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as marker of I/R injury.
Interventions
The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
Sponsors
Study design
Eligibility
Inclusion criteria
* Age \> 18 years * Major liver resection (hemihepatectomies and extended hemihepatectomies) for benign and malignant lesions * Macroscopic and microscopic normal liver parenchyma * No underlying liver disease * Normal preoperative liver tests (quick, bilirubin, AST, ALT) * Signed informed consent
Exclusion criteria
* Age \< 18 years * Minor liver resections (less than hemihepatectomies) or wedge resections * Macroscopic and microscopic appearance of liver fibrosis or cirrhosis * Underlying liver disease such as viral hepatitis, cirrhosis, etc. * Pathological preoperative liver tests (quick, bilirubin, AST, ALT) * Intolerance to xanthine derivatives * History of myocardial or cerebrovascular insult * Total vascular exclusion during liver resection * Intra-operative detection of unresectable tumor disease * No signed informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| I. To determine the regeneration of the liver after liver resection with and without PTF treatment | pre- and up to day 8 after liver resection |
Secondary
| Measure | Time frame |
|---|---|
| Il-6, TNF, procalcitonin for regeneration.AST & ALT peak for ischemic reperfusion injury. If PTF treatment has protective effects in steatotic/fibrotic liver. | pre- and up to 8 days postoperatively |
Countries
Switzerland